The Ability of Vaped Marijuana to Reduce the Severity ofNaloxone-Precipitated Withdrawal
Sponsor: |
National Institute on Drug Abuse |
Enrolling: |
Male and Female Patients |
Study Length: |
28 Days |
IRB Number: |
8061 |
U.S. Govt. ID: |
NCT05114460 |
Contact: |
Jermaine Jones: 646-774-6113 / jermaine.jones@nyspi.columbia.edu |
Naloxone-induced withdrawal is also common in out-of-hospital settings in which non-medical persons are asked to administer naloxone to save the lives of their peers. Concerns about the adverse effects of naloxone administration may prevent or delay the use of this lifesaving intervention. The goal of the proposed, proof-of-concept study is to test the combined effects of vaporized marijuana Delta-9-tetrahydracannabinol (THC) with naloxone as a proof of concept towards the possible development of a combined overdose reversal agent with improved tolerability.
This study is closed
Investigator
Jermaine Jones, PhD
Are you between the ages of 18-55? |
Yes |
No |
Do you use opioids like heroin or fentanyl? |
Yes |
No |
Are in in treatment for opioid use disorders (e.g., methadone or buprenorphine)? |
Yes |
No |